The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models
Chiara Tarantelli, Filippo Spriano, Elisa Civanelli, Luca Aresu, Giorgia Risi, Eleonora Cannas, Omar Kayali, Luciano Cascione, Alberto J. Arribas, Anastasios Stathis, Young Hee Ko, Francesco Bertoni
This study evaluates KAT/3BP, a 3BP derivative, showing in vitro and in vivo anti-tumor activity against lymphoma models, including resistant cell lines and synergistic effects with existing therapies.
bioRxiv · Apr 23, 2025 · PreprintCancer Biology